TNFRSF17 and plasma cell myeloma: Targeting BCMA enables the selective eradication of myeloma cells that overexpress the antigen, with potential off-target effects predominantly restricted to healthy BCMA-expressing plasma cells and plasmablasts, as well as a specific subset of memory B cells [54,55] The CAR we selected for our research was initially developed for CAR-T therapy, where it has demonstrated exceptional efficacy [26].